Procter & Gamble reported quarterly earnings of $1.88 per share, narrowly surpassing consensus estimates by $0.02 and matching the prior year’s EPS. Revenue of $22.21 billion was up 1.5% year-over-year, modest growth that the market had largely discounted. Management set full-year 2026 EPS guidance at a range of 6.830 to 7.090, underscoring confidence in cash flow generation. With a quarterly dividend of $1.0568 (annualized $4.23) and a payout ratio of 62.7%, P&G’s ability to sustain and potentially grow distributions remains intact despite operating near a multi-year low in share valuation. A 19.3% net margin and 32.1% return on equity further demonstrate the business’s enduring profitability and capital efficiency.

In the most recent 13F filing for Q3, GDS Wealth Management raised its stake in Procter & Gamble by 20.9%, acquiring an additional 14,060 shares to reach 81,190 shares valued at $12.48 million. Other notable moves include BAM Wealth Management’s $678,000 new position, Acorn Wealth Advisors’ 4.5% increase to 4,028 shares, and PFG Investments’ 1.6% boost to 54,237 shares. Symphony Financial and Inlet Private Wealth each lifted holdings by around 1.9% and 1.6%, respectively. Institutional ownership stands at 65.77%, reflecting continued confidence from large asset managers in P&G’s cash flow stability and dividend yield.

Equity research firms have grown more constructive: JPMorgan Chase & Co. upgraded P&G to “overweight” with a target of $165, UBS raised its price objective to $170 with a “buy” rating, Piper Sandler initiated coverage at “neutral” with a $150 target, Wells Fargo assigned “overweight” at $165, and Raymond James maintained an “outperform” stance with a $175 target. Fourteen analysts recommend Buy, eight advise Hold, and the consensus price target sits at $166.70. This analyst alignment, coupled with P&G’s dividend yield of approximately 2.8%, positions the stock as a moderate buy for investors seeking both income and steady long-term compounding potential.